Nirrin ATLAS® and TALOS™: An Honest Review of a Vendor-Only Sourcing Base
Sourcing transparency: this is not a peer-reviewed literature review
Every other vendor review on this site (Hamilton VisiFerm, Mettler Toledo InPro 6950i, PreSens PSt3, Aber FUTURA, Optek ASD, Pyroscience FP-O2, PendoTECH, Kaiser Raman, Hamilton Incyte) is built from a minimum of three peer-reviewed deployment studies of the specific instrument in a real bioreactor. For Nirrin's ATLAS® and TALOS™ NIR-HPTLS platforms, that literature does not yet exist. As of 2026-09-30, a PubMed search for "Nirrin" combined with any bioreactor, bioprocess, NIR, laser, or tunable-spectroscopy term returned zero hits.
The performance claims below therefore trace to five source classes, tagged inline throughout the page and colour-coded in the references list: vendor Nirrin's product pages, press releases, and sponsored webcast; distributor the Dr. Marino Müller AG product listing; patent the granted US 12,222,279 B2 flow-cell patent; grant the 2024 NIH SBIR grant announcement; and class the adjacent peer-reviewed NIR- and PAT-bioprocess literature that does not name Nirrin's specific instruments but establishes the physical class they belong to.
Treat vendor-reported figures as a starting point for scoping and not as a substitute for on-site trial data with your matrix. When Nirrin's 2024 NIH SBIR-driven academic collaborations reach publication, this page will be revised. If you have deployed ATLAS® or TALOS™, please contribute your experience in the reviews section below.
Nirrin's ATLAS® (multi-analyte at-line and in-line) and TALOS™ (protein-focused at-line, with in-line and in situ variants in development) sit in the same market slot as legacy Fourier-transform NIR benchtop analysers (Bruker MPA II, Metrohm NIRS DS2500, ABB FTLA2000-series) and modern real-time PAT bioprocess spectrometers (Sartorius BioPAT Spectro, Endress+Hauser NIR probes). Nirrin's core differentiator is the tunable narrow-band laser: instead of scanning a broad NIR spectrum with white light and a monochromator, HPTLS scans a narrow window with a coherent laser, giving what the vendor claims is a 20× lower detection limit at roughly 1/10 the acquisition time. Independent peer-reviewed validation is pending; the platform is worth a trial evaluation for downstream/formulation buffer and protein quantitation, but not yet a purchase decision made on published third-party evidence.
The Nirrin platform at a glance
Nirrin Technologies (Cambridge, Massachusetts, USA) commercialises the HPTLS™ (High-Precision Tunable Laser Spectroscopy) platform. Two named products ship today: TALOS™ (direct protein quantitation, 0.1–250 mg/mL, launched June 2026) and ATLAS® (multi-analyte platform for proteins, buffer excipients, surfactants, launched at BPI July 2024). Both are marketed for at-line pipetted sample analysis, with in-line flow-cell and in situ probe variants either shipping (ATLAS) or in development (TALOS). Details below are drawn from the Nirrin product pages, the Dr. Marino Müller AG distributor listing, and the associated press releases — not from an independent deployment study.
| Specification | Vendor-reported value |
|---|---|
| Measurement principle | NIR-HPTLS™ (High-Precision Tunable Laser Spectroscopy), fixed 1 mm optical path between two sapphire rods, narrow-band tunable diode laser in the NIR combination-band region vendor patent |
| Wavelength range (TALOS™) | 2100–2350 nm (NIR combination band, targeting peptide backbone signatures) vendor |
| Wavelength range (ATLAS®) | Tunable laser reportedly "spans 300 nm, significantly broader than conventional tunable lasers"; exact band centre not disclosed in public materials vendor |
| Measurement range (TALOS, protein) | 0.1–250 mg/mL, no dilution required vendor |
| Accuracy (TALOS, vendor claim) | ±2% across full range; R² = 0.9998 vs. orthogonal reference methods; ≤1% RSD measurement-to-measurement vendor |
| Accuracy (ATLAS, vendor claim) | ±5% accuracy with ±1% precision measurement-to-measurement distributor |
| Sample volume (at-line) | 15 µL pipetted onto pedestal vendor |
| Sample volume (in-line flow cell) | 10 µL – 1 mL selectable dead volume vendor |
| Time to result | 25 scans in <1 s (spectral acquisition); <3 min end-to-end time-to-answer vendor distributor |
| Comparison to FT-NIR (vendor) | 20× lower detection limit than Fourier-transform NIR at ~1/10 the acquisition time (~10–20 min for equivalent FT-NIR SNR) vendor |
| Calibration approach | "No calibration curve, no extinction coefficient, no multivariate PLS model" per vendor material; preloaded analyte library used for identification and quantitation vendor |
| Deployment modes | At-line (shipping); in-line flow cell (ATLAS shipping, TALOS in development); in situ probe (ATLAS shipping, TALOS in development) vendor |
| Regulatory features | GMP-ready at-line configurations with 21 CFR Part 11-capable workflows; spectral residual and measurement-quality metrics included; in-line/in situ GMP support forthcoming vendor |
| Flow cell patent | US 12,222,279 B2 granted 2025 — covers active temperature regulation, precise optical path length control, versatile form factor for in-bioprocess optical analysis patent |
| Typical capital cost | Not published in the public domain; Nirrin sells through direct sales in the US and via Dr. Marino Müller AG in EU/CH; expect PAT-analyser class pricing (typically $75k–$250k depending on configuration and connectivity) class |
What the manufacturer publishes about performance
Every performance figure below is drawn from Nirrin's own materials, its distributor, its granted flow-cell patent, or a sponsored BioProcess International webcast. None has been reproduced in a peer-reviewed deployment study of Nirrin's specific instruments [1][2][3][6]. We are stating this at the top of the section, on the SVG figure, in the spec table, and beside every specific number, so the source cannot get lost.
The TALOS™ protein quantitation system, launched at BIO 2026 and described in Nirrin's June 2026 press release [4], is marketed for direct quantitation of monoclonal antibodies, peptides, vaccines, and viral capsids in the 0.1–250 mg/mL range from a 15 µL pipetted sample. The vendor's marketing headline is "no dilution, no moving optics, no molecule-specific calibration, no manual pathlength adjustment," achieved through a fixed 1 mm path defined by two sapphire rods and a tunable NIR laser scanning 2100–2350 nm. Bryan Hassell (Nirrin CEO) is quoted as saying traditional UV-based workflows "introduce operational complexity" and TALOS provides "a more reliable and transferable approach to protein quantitation" [4]. TALOS won an R&D100 Award in 2026 [1].
The ATLAS® multi-analyte platform, launched July 2024, is Nirrin's earlier and broader product [5][6]. Where TALOS targets protein-only quantitation, ATLAS is marketed as a "point-of-sampling core-lab replacement" that measures proteins, buffer excipients (histidine, sucrose), surfactants, stabilisers, and product-quality-related attributes (charge variants, glycoforms, aggregation) from a single 15 µL sample in under a minute. Nirrin quotes 10 top global pharmaceutical companies as early adopters [6], though these companies are not named. The distributor listing quantifies ATLAS at ±5% accuracy with ±1% precision [3]. The most prominent claim is a case study in which ATLAS reportedly quantified surfactants accurately in protein-containing matrices where traditional HPLC showed "significant under-recovery" in samples containing sucrose, histidine, and high-concentration protein; this is described in a sponsored BioProcess International webcast recap [7] and has not been independently replicated.
The flow-cell patent (US 12,222,279 B2, granted 2025) covers the in-line implementation and, according to Nirrin's press release [8], integrates three design elements: active temperature regulation of the sensing volume, precise optical path length control, and a versatile form factor designed to sit across upstream, downstream, and formulation workflows. Bryan Hassell (Nirrin CTO) frames the patent as enabling "more consistent, high-quality data." The patent document is on file with USPTO; the underlying claim performance in a specific bioreactor is not yet independently peer-reviewed.
In September 2024 the NIH awarded Nirrin a $2M SBIR grant to expand the HPTLS platform for biomanufacturing [9]. The grant is expected to fund the academic collaborations that would generate the first independent deployment publications; those papers had not appeared as of this page's 2026-09-30 publication date. When they do, this page will be revised and each claim linked to a citation of the specific instrument in a named process.
Vendor-reported performance data
The table below aggregates the specific numbers Nirrin publishes. Every row is tagged with the source class; none is a peer-reviewed deployment.
| Source | Claim / condition | Value | Where the number lives |
|---|---|---|---|
| [1] | TALOS accuracy vs. orthogonal reference (vendor) | R² = 0.9998; ±2% across full range | Nirrin TALOS product page (2026) |
| [1] | TALOS precision (vendor) | ≤1% RSD measurement-to-measurement | Nirrin TALOS product page (2026) |
| [1] | TALOS dynamic range (vendor) | 0.1–250 mg/mL protein, no dilution | Nirrin TALOS product page (2026) |
| [3] | ATLAS accuracy (distributor) | ±5% accuracy, ±1% precision | Dr. Marino Müller AG product listing |
| [7] | HPTLS vs Fourier-transform NIR detection limit (vendor) | 20× lower LOD in ~1/10 the acquisition time | Sponsored BPI webcast recap |
| [7] | HPTLS scan-count claim (vendor) | 25 scans in <1 s vs. 1,000+ scans (10–20 min) for FT-NIR | Sponsored BPI webcast recap |
| [6] | ATLAS early adopters (vendor) | 10 top global pharmaceutical companies (unnamed) | GEN news article, July 2024 |
| [7] | Surfactant-in-matrix case study (vendor) | ATLAS accurate where HPLC showed "significant under-recovery" in sucrose/histidine/high-protein matrix | Sponsored BPI webcast recap |
Every row is a vendor, distributor, or sponsored publication — not an independent peer-reviewed deployment. This table exists so the sourcing cannot be misread.
Class-level context from the peer-reviewed NIR-bioprocess literature
Since no peer-reviewed literature names Nirrin's specific instruments, the honest way to contextualise the vendor's claims is against the broader NIR-in-bioprocess literature, which is well-developed. Three anchor references frame the class.
Class R² ceilings. Roychoudhury et al. 2007 (PMC6527534) reported on-line glucose monitoring in mammalian cell culture using benchtop NIR spectroscopy across scale-up from 2 L to 2,500 L and achieved calibration R² in the 0.98–0.99 range against off-line HPLC [10]. Nirrin's claim of R² = 0.9998 for protein quantitation is one order of magnitude tighter than typical NIR-in-bioprocess literature ceilings; the plausibility of that number cannot be evaluated without independent replication.
PAT spectroscopy for biopharmaceuticals. The Esmonde-White et al. 2017 and 2022 reviews (Analytical and Bioanalytical Chemistry) [11] map the state-of-the-art for Raman and NIR spectroscopy in bioprocess monitoring. Both reviews position tunable-laser NIR as an emerging alternative to FT-NIR benchtops and Raman probes, with the key trade-off being spectral coverage (Raman > FT-NIR > narrow-band tunable NIR) against detection sensitivity per unit acquisition time (tunable laser > FT-NIR > broad Raman with autofluorescence). Nirrin's positioning is consistent with this framework; whether HPTLS achieves the specific 20× LOD improvement Nirrin claims has not been tested outside vendor material.
NIR for UF/DF and formulation. Cell-culture NIR (glucose, lactate, glutamine on-line) has a longer literature base than downstream/formulation NIR, but the latter is growing rapidly. Independent studies (Cervera et al., Rodrigues et al., Buckley & Ryder reviews) show that NIR CAN quantify protein concentration and buffer excipients in downstream matrices with acceptable accuracy, provided a multivariate model is trained on process-representative samples [11]. Nirrin's claim of "no multivariate model required" is a departure from this literature consensus and, if it holds up in independent hands, would be a meaningful advance. It has not yet been independently tested.
Limitations that follow from the sourcing base
Because the evidence base is entirely vendor and patent material, the limitations of this page are the limitations of that evidence. Each is stated bluntly.
- No independent replication of the R² = 0.9998 claim. The published NIR-in-bioprocess literature [11] tends to ceiling around R² = 0.97–0.99 for protein and metabolite quantitation with well-trained PLS models on well-controlled matrices. Nirrin's R² = 0.9998 claim [1] is one to two orders of magnitude tighter and needs independent verification before it should be relied on for a purchase decision.
- No high-cell-density or bioreactor-fouling data. The vendor's case studies are all in relatively clean matrices (buffer prep, UF/DF permeate, at-line samples). The class-level NIR literature [11] shows that NIR performance degrades in high-cell-density culture and fouled or bubble-perturbed windows. Nirrin has not published data at >100 g/L wet cell weight, in the presence of antifoam, or after extended CIP/SIP cycling of an in-line flow cell.
- No named commercial customer. Nirrin claims 10 top global pharmaceutical companies as early adopters [6] but does not name any. For a purchase decision, ask Nirrin to name at least one named-customer reference in a comparable process, ideally one that is willing to speak to the accuracy and drift of the instrument in a real production setting.
- In-line and in situ TALOS variants are in development, not shipping. The current TALOS product is at-line only [1]. The ATLAS in-line flow cell is shipping and is the subject of the 2025 flow-cell patent [8]. Confirm the exact configuration and shipping date with Nirrin before writing HPTLS into a URS or PAT strategy document.
- "No multivariate model" is a strong claim. Every other narrow-band NIR platform on the market uses PLS or similar chemometric modelling to convert absorbance to concentration in a real matrix. Nirrin's claim of a preloaded analyte library that avoids per-user model training [1][2] departs from the class norm and is worth testing on your specific matrix as part of any trial evaluation.
- Vendor pricing is not public. No public price is quoted in Nirrin, distributor, or news material. Expect PAT-analyser class pricing ($75k–$250k depending on configuration) and budget for both capital and the qualification/method-transfer effort required to bring any new PAT instrument into a validated environment.
When Nirrin's HPTLS platform is worth evaluating
Consider ATLAS® or TALOS™ for
- Point-of-sampling at-line protein quantitation across a wide 0.1–250 mg/mL range without dilution [1]
- UF/DF process monitoring where you need simultaneous protein and buffer-excipient readback in seconds rather than the ~4–6 week core-lab HPLC turnaround Nirrin cites [6]
- Surfactant quantitation in protein-containing matrices where HPLC under-recovery has been an issue [7] (worth trialling on your specific formulation)
- Formulation and buffer-prep QC as a same-day feedback loop rather than a next-week analytical report [6]
Do NOT rely on it yet for
- Purchase decisions grounded in third-party independent evidence — the peer-reviewed deployment literature does not exist yet [11]
- High-cell-density in-line upstream monitoring — Nirrin has not published data in that regime and the class-level NIR literature warns about it [11]
- GMP in-line or in situ deployment on TALOS today — only the at-line configuration has 21 CFR Part 11 support at time of writing [1]
- Replacing a validated release-testing HPLC assay — without independent method-comparability data, HPTLS is a screening / monitoring tool, not a release-grade replacement [11]
Use cases Nirrin publishes
Each card summarises a use case Nirrin describes in vendor material. Each is a vendor-reported claim, not an independently replicated deployment.
Real-time UF/DF monitoring
Nirrin markets ATLAS for real-time monitoring and control of ultrafiltration/diafiltration operations, reading protein concentration and buffer excipient composition on the retentate side to signal end-of-diafiltration.
[6]Poloxamer / polysorbate in a protein matrix
Vendor case study describes HPTLS quantifying surfactant concentration in samples containing sucrose, histidine, and high-concentration protein — a matrix where the vendor claims HPLC showed significant under-recovery.
[7]mAb, peptide, and vaccine concentration
TALOS is marketed for 0.1–250 mg/mL protein quantitation in seconds from a 15 µL sample, replacing UV A280 workflows that the vendor characterises as introducing "operational complexity" and cross-molecule extinction-coefficient assumptions.
[1] [4]Buffer exchange and excipient QC
ATLAS is marketed for buffer preparation quality control and buffer-exchange monitoring, quantifying histidine, sucrose, and stabiliser concentrations against a preloaded analyte library.
[2] [6]Comparing Nirrin HPTLS against Raman and legacy NIR?
The Sensor Selection Tool takes 6 questions about your scale, modality, analytes, and budget and returns ranked PAT-instrument recommendations — including how Nirrin's tunable-laser NIR compares against Raman probes (Kaiser, Endress+Hauser) and legacy FT-NIR benchtops (Bruker, Metrohm, Sartorius).
Open the Sensor Selection ToolUser reviews from bioprocess engineers
If you have deployed the Nirrin ATLAS® or TALOS™, your experience is exactly what this page is missing. Two minutes, anonymous option available — and your submission fills the peer-review gap this page currently discloses.
Frequently asked questions
Are there independent peer-reviewed studies of the Nirrin ATLAS or TALOS?
What does the Nirrin HPTLS technology actually measure?
What accuracy does Nirrin publish for ATLAS and TALOS?
What deployment configurations does Nirrin sell?
What is Nirrin's granted flow-cell patent actually claiming?
What analytes does Nirrin say ATLAS can measure?
Where does the Nirrin platform sit versus Raman and legacy FT-NIR?
Should I trust vendor-reported sensor performance figures?
References
Colour-coded by source class so a reader can see at a glance what kind of evidence supports each claim. vendor Nirrin, distributor, or sponsored publication. patent Granted US utility patent. class Independent peer-reviewed literature that anchors the NIR-bioprocess class the Nirrin instrument sits in but does not name the specific instrument.
- Nirrin Technologies (2026). TALOS™ — Protein quantitation that doesn't slow you down. Product page. nirrin.tech/talos. vendor
- Nirrin Technologies (2026). Quantitative measurements for complex bioprocesses. Company overview. nirrin.tech. vendor
- Dr. Marino Müller AG (2025). Nirrin Atlas — product listing. Swiss distributor page. muellerag.ch/product/atlas. distributor
- BioSpace / BusinessWire (2026-06-03). Nirrin Technologies Launches TALOS™, a Protein Quantitation System Designed for Modern Biopharmaceutical Manufacturing Workflows. biospace.com. vendor press
- Technology Networks (2026). Direct Protein Quantitation Platform Launches. technologynetworks.com. vendor press syndication
- Genetic Engineering & Biotechnology News (2024-07-09). Nirrin Launches Atlas for At-Line Analysis at the Point of Sampling. genengnews.com. vendor press
- BioProcess International (2024). Big Impact from Small Samples: Harnessing HPTLS for Complex Bioprocess Analysis — Webcast Recap. Sponsored content. bioprocessintl.com. sponsored webcast recap
- BioSpace / GEN (2025). Nirrin Technologies Granted Patent for Cutting-Edge Flow-Cell Technology, Advancing Real-time Bioprocess Monitoring. Press release for US Patent 12,222,279 B2. genengnews.com. patent
- BusinessWire (2024-09-04). NIH Awards Nirrin Technologies $2M SBIR Grant to Expand Development of HPTLS Technology Platform for Biomanufacturing. businesswire.com. grant announcement
- Roychoudhury P, McMillan L, Wang X, Bishop L (2007). On-line glucose monitoring by near infrared spectroscopy during the scale up steps of mammalian cell cultivation process development. Bioprocess and Biosystems Engineering. PMC6527534. DOI: 10.1007/s00449-006-0092-x. class-level NIR bioprocess
- Esmonde-White KA, Cuellar M, Uerpmann C, Lenain B, Lewis IR (2017); Esmonde-White KA, Cuellar M, Lewis IR (2022). Raman spectroscopy as a process analytical technology for pharmaceutical manufacturing and bioprocessing / The Role of Raman Spectroscopy in Biopharmaceuticals. Analytical and Bioanalytical Chemistry. DOI: 10.1007/s00216-016-9974-1 and 10.1007/s00216-021-03727-4. class-level PAT spectroscopy